Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

N-(bromoacetyl)-3,3-dinitroazetidine

EU orphan designation number: EU/3/17/1966   
Active ingredient: N-(bromoacetyl)-3,3-dinitroazetidine
Indication: Treatment of small cell lung cancer
Sponsor: Sirius Regulatory Consulting EU Limited
The Black Church, ST. Mary's Place, Dublin D07 P4AX, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
19/01/2018 Orphan designation EMA/OD/166/17 (2018)388 of 17/01/2018
22/10/2018 Transfer of orphan designation (2018)6986 of 18/10/2018